3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
7
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
439
Neoplasms
364
Breast Neoplasms
261
Colorectal Neoplasms
245
Neoplasm Metastasis
217
Melanoma
210
Leukemia, Myeloid, Acute
188
Multiple Myeloma
187
Pancreatic Neoplasms
183
Ovarian Neoplasms
181
Recurrence
175
Prostatic Neoplasms
161
Lymphoma, Non-Hodgkin
142
Stomach Neoplasms
133
Squamous Cell Carcinoma of Head and Neck
128
Lung Neoplasms
126
Lymphoma
121
Carcinoma, Hepatocellular
117
Carcinoma, Renal Cell
102
Triple Negative Breast Neoplasms
100
Leukemia, Lymphocytic, Chronic, B-Cell
99
Glioblastoma
98
Advanced Solid Tumor
94
Leukemia
93
Small Cell Lung Carcinoma
91
Lymphoma, Large B-Cell, Diffuse
90
Head and Neck Neoplasms
87
Advanced Solid Tumors
85
Endometrial Neoplasms
81
Myelodysplastic Syndromes
78
Interventions
derazantinib
2
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
Acrocephalosyndactylia
×
Clear all
NCT04604132
2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2
Terminated
47 enrolled
22 charts
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts